148 related articles for article (PubMed ID: 12876897)
21. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
22. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Gao WY; Johns DG; Tanaka M; Mitsuya H
Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
[TBL] [Abstract][Full Text] [Related]
23. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
[TBL] [Abstract][Full Text] [Related]
24. First-line antiretroviral therapy in resource-limited settings: time to reconsider?
Adlington R; Richens J; Shahmanesh M
J Infect Dis; 2009 May; 199(9):1407; author reply 1407-8. PubMed ID: 19358673
[No Abstract] [Full Text] [Related]
25. The role of stavudine in the management of adults with HIV infection.
Moyle GJ; Gazzard BG
Antivir Ther; 1997 Dec; 2(4):207-18. PubMed ID: 11327440
[TBL] [Abstract][Full Text] [Related]
26. Study on mutations and antiretroviral therapy (SMART): preliminary results.
Gianotti N; Moretti F; Tambussi G; Racca S; Presi S; Crucianelli R; Carrera P; Ferrari M; Lazzarin A
Antivir Ther; 1999; 4 Suppl 3():65-9. PubMed ID: 16021873
[TBL] [Abstract][Full Text] [Related]
27. Antiretroviral drug resistance.
Japour AJ
AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
[TBL] [Abstract][Full Text] [Related]
29. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Winston A; McAllister J; Amin J; Cooper DA; Carr A
HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
[TBL] [Abstract][Full Text] [Related]
30. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
[TBL] [Abstract][Full Text] [Related]
33. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E
Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228
[TBL] [Abstract][Full Text] [Related]
34. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
[TBL] [Abstract][Full Text] [Related]
35. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
[TBL] [Abstract][Full Text] [Related]
36. New questions about an old combination--ddI + d4T.
Proj Inf Perspect; 2003 Jan; (35):13-4. PubMed ID: 12647675
[TBL] [Abstract][Full Text] [Related]
37. Reevaluating initial therapy.
Cadman J
GMHC Treat Issues; 1998 Feb; 12(2):1-5. PubMed ID: 11365217
[TBL] [Abstract][Full Text] [Related]
38. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors.
Geretti AM
AIDS Rev; 2006; 8(4):210-20. PubMed ID: 17219736
[TBL] [Abstract][Full Text] [Related]
40. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
Liu L; Lu HZ; Henry M; Tamalet C
J Med Virol; 2007 Oct; 79(10):1593-9. PubMed ID: 17705165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]